bluebird bio, Inc. (NASDAQ:BLUE) Insider David Davidson Sells 1,200 Shares
bluebird bio, Inc. (NASDAQ:BLUE) insider David Davidson sold 1,200 shares of the firm’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $100.49, for a total value of $120,588.00. Following the sale, the insider now directly owns 16,077 shares of the company’s stock, valued at $1,615,577.73. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
David Davidson also recently made the following trade(s):
- On Tuesday, August 1st, David Davidson sold 3,000 shares of bluebird bio stock. The stock was sold at an average price of $92.37, for a total value of $277,110.00.
- On Wednesday, July 5th, David Davidson sold 5,000 shares of bluebird bio stock. The stock was sold at an average price of $105.28, for a total value of $526,400.00.
- On Monday, June 5th, David Davidson sold 1,000 shares of bluebird bio stock. The stock was sold at an average price of $90.00, for a total value of $90,000.00.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 1.77% during midday trading on Friday, hitting $95.05. The stock had a trading volume of 599,783 shares. The company’s market cap is $4.33 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75. The company’s 50 day moving average is $102.86 and its 200 day moving average is $88.98.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.66) by $0.07. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The firm’s revenue was up 977.4% compared to the same quarter last year. During the same period last year, the business posted ($1.59) EPS. On average, analysts anticipate that bluebird bio, Inc. will post ($6.69) earnings per share for the current year.
Several research firms have recently weighed in on BLUE. BTIG Research reiterated a “buy” rating and set a $112.00 price target on shares of bluebird bio in a research note on Thursday, June 1st. Zacks Investment Research downgraded bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub downgraded bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday. Maxim Group upgraded bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Friday, June 2nd. Finally, Wedbush restated an “outperform” rating on shares of bluebird bio in a research note on Tuesday, June 6th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $100.54.
Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock worth $289,259,000 after buying an additional 3,175,124 shares during the last quarter. Norges Bank acquired a new stake in bluebird bio during the fourth quarter worth $22,940,000. MARSHALL WACE ASIA Ltd acquired a new stake in bluebird bio during the first quarter worth $18,006,000. Marshall Wace North America L.P. acquired a new stake in bluebird bio during the first quarter worth $18,006,000. Finally, Vanguard Group Inc. boosted its stake in bluebird bio by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,215,246 shares of the biotechnology company’s stock worth $292,266,000 after buying an additional 141,293 shares during the last quarter.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.